



10745 Westside Way, Suite 200,  
Alpharetta, GA 30009  
Tel: +1 (844) 884 5367  
Email: [info@vtivision.com](mailto:info@vtivision.com)  
[www.vtvision.com](http://www.vtvision.com)  
[www.vtvisioninvestors.com](http://www.vtvisioninvestors.com) (for investors)

## ASX Announcement

**Atlanta, Georgia, USA 2 November 2017:** Visioneering Technologies, Inc. (ASX: VTI) announced today that Mr. Gary Stevenson has resigned from the Board of Directors. MB Venture Partners, at which Mr. Stevenson is the Managing Partner, has been represented on the VTI board since 2008.

“We at VTI have enjoyed working with Gary over the years, are very appreciative of his contributions, and wish Gary well. We have begun a search to add an independent Non-Executive Director to the Board,” commented Stephen Snowdy, PhD, CEO of VTI.

### For more information, please contact:

Stephen Snowdy  
CEO, Visioneering Technologies, Inc.  
Email: [ssnowdy@vtivision.com](mailto:ssnowdy@vtivision.com)

### About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. VTI also sells and plans additional contact lens products.

### Foreign ownership restrictions:

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.